American Society of Retina Specialists 23rd Annual Meeting July 16-20, 2005; Montreal, Canada Summarized by David S. Boyer, MD University of Southern California Los Angeles, California Supported by an unrestricted educational grant from

MARINA PHASE 3 STUDY: 1-YEAR FINDINGS 716 patients with minimally classic or occult CNV from AMD with recent disease progression were treated with placebo, 0.3 mg ranibizumab, or 0.5 mg ranibizumab 716 patients with minimally classic or occult CNV from AMD with recent disease progression were treated with placebo, 0.3 mg ranibizumab, or 0.5 mg ranibizumab Miller J, Chung CY, Kim RY, MARINA Study Group. (62%, 4.6%, 11%) (94.5%, 24.8%, 38%) (94.6%, 33.8%, 40%)

MARINA PHASE 3 STUDY: 1-YEAR FINDINGS (continued) No significant intraocular inflammation was seen No significant intraocular inflammation was seen No significant systemic side effects (hypertension, MI, CVA, death) No significant systemic side effects (hypertension, MI, CVA, death)

FOCUS: PHASE 1/2 STUDY 162 patients 162 patients Compared ranibizumab in combination with PDT vs PDT alone Compared ranibizumab in combination with PDT vs PDT alone Ranibizumab PDT + PDT alone Ranibizumab PDT + PDT alone 3 line or less VA loss90.5% 67.9% 3 line or less VA loss90.5% 67.9% 3 line or more VA gain23.8% 5.5% 3 line or more VA gain23.8% 5.5% Severe vision decrease < 1% 9.0% Severe vision decrease < 1% 9.0% Heier JS, FOCUS Study Group.

FOCUS: PHASE 1/2 STUDY (continued) Ranibizumab + PDT vs PDT alone had a 13- letter difference (+5 letters, -8 letters, respectively) Ranibizumab + PDT vs PDT alone had a 13- letter difference (+5 letters, -8 letters, respectively) Side effects Side effects  5% presumed endophthalmitis  9% uveitis* * All uveitis events occurred prior to a protocol change in time interval between intravitreal injection of ranibizumab and PDT.

IMT002: 1-YEAR RESULTS OF THE PHASE 2/3 STUDY 206 patients (aged 55 years or older) with moderate to profound VA loss (20/80-20/800) were implanted with the IMT002 intraocular telescope 206 patients (aged 55 years or older) with moderate to profound VA loss (20/80-20/800) were implanted with the IMT002 intraocular telescope After 1 year, BCVA using EDTRS vision: After 1 year, BCVA using EDTRS vision:  Mean distance improvement: 20/316 to 20/147  Near VA 8 ": 20/156 to 20/89  Near VA 16 ": 20/240 to 20/146 Hudson HL and Chang T.

IMT002: 1-YEAR RESULTS OF THE PHASE 2/3 STUDY (continued) VFQ 25 and ADL showed statistically significant improvement VFQ 25 and ADL showed statistically significant improvement Corneal endothelial cell loss at 1 year: 25.3% Corneal endothelial cell loss at 1 year: 25.3%